Trial · NCT07893535
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Escalation Phase: Number of Participants with Dose-limiting Toxicities (DLTs) | Up to approximately 1 month | |
| Primary | Dose Escalation Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs) | From first dose of study drug until 30 days after last dose, up to approximately 24 months. | |
| Primary | Dose Expansion Phase: Objective Response Rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) with confirmation per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. |
| Secondary | Dose Escalation Phase: Objective Response Rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) with confirmation per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. |
| Secondary | Duration of Response (DOR) | Up to approximately 24 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) at Week 12 and Week 24 | Week 12 and Week 24 | DCR at 12 weeks and 24 weeks is defined as the percentage of participants who have CR, PR, or stable disease (SD) according to RECIST v1.1, and are alive and progression-free at the Week 12 and Week 24 assessment, respectively. |
| Secondary | Dose-Expansion Phase: Progression-free Survival (PFS) | Up to approximately 24 months | PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Serum Concentration of BON-106 | Up to approximately 24 months | |
| Secondary | Maximum Observed Concentration of BON-106 | Approximately 2 months | |
| Secondary | Area Under the Concentration-time Curve (AUC) of BON-106 | Approximately 2 months | |
| Secondary | Elimination Half-life (t1/2) of BON-106 | Approximately 2 months | |
| Secondary | Dose- Expansion Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | From first dose of study drug until 30 days after last dose, up to approximately 24 months. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07893535/registered